Monthly Archives: January 2012

Investment terror

Posted on January 31, 2012 by

Latha Jishnu Issue: Jan 31, 2012 Source: Down to Earth Since the 1990s developing nations have been on a treaty spree, signing a vast number of bilateral and regional investment treaties to attract funds for development. But as the figure … Continue reading →

Posted in EU-India FTA, Investment treaties, investor state dispute | Leave a comment

India may exclude clause on lawsuits from trade pacts

Posted on January 30, 2012 by

Source: Livemint, 29 Jan 2012 Asit Ranjan Mishra The DIPP which allows firms of the partner country investing in India to take legal action against the govt at a global forum in case of any dispute has in principle decided not … Continue reading →

Posted in EU-India FTA, Investment treaties, investor state dispute | Leave a comment

EU Commission propaganda on ACTA

Posted on January 28, 2012 by

January 26, 2012 By Ante The European Commission published a document in defense of ACTA, “10 Myths about ACTA“. It is pure propaganda. The document is widely distributed by polish authorities. Let’s take a look. Myth 1: ACTA is a … Continue reading →

Posted in ACTA, Generic drug, IP Rights | Leave a comment

EU & India will agree and finalize polictical framework for FTA during Summit: Discussions on Pharmaceuticals have progressed significantly says EU Ambassador

Posted on January 27, 2012 by

There have been several media reports stating that Indian and EU will not be signing the agreement in the Summit agree to a political framework during the Summit which will be held in Delhi on 10 Feb 2012. However, the … Continue reading →

Posted in EU-India FTA, IP Rights | Leave a comment

The TPP and what it could mean for you

Posted on January 24, 2012 by

Source: www.3news.co.nz MON, 23 JAN 2012 1:14P.M. By James Murray Click on the video tab here to listen to an interview with Professor Kelsey – she talks about the impact TPP could have on pharmaceuticals and tobacco control and whether … Continue reading →

Posted in patent evergreening, Patent linkages, Patent Opposition, Patent Term Extension, Pharmaceutical Benefits Scheme, Trans-Pacific Partnership Agreement | Leave a comment

EU-INDIA FTA – JOIN THE DELHI RALLY, 10th FEB 2012

Posted on January 24, 2012 by

Dear Comrades, Last year on 2nd March we did a massive rally which shock the EU-India negotiation to certain/larger extend. DATA EXCLUSIVITY and PATENT TERM extension were off the table, I must  say because of our rally, yet there are … Continue reading →

Posted in data exclusivity, EU-India FTA | Leave a comment

Petition: Join the global campaign against Novartis

Posted on January 21, 2012 by

Novartis: Take your claws off our medicines !  India is known as the ‘Pharmacy of the developing world’ for producing and supplying affordable generic drugs to more than 150 developing countries in Asia, Africa and Latin America. But India’s capacity … Continue reading →

Posted in Generic drug, Indian Patent Law, Novartis Case, Sec 3 (d) | Tagged , , , | Leave a comment

Pharmabiz: Compulsory license ensures patent rights & public health

Posted on January 18, 2012 by

Nandita Vijay, Bengaluru Source: Pharmabiz Wednesday, January 18, 2012, 08:00 Hrs [IST] Compulsory license, specifically under Section-92A of the Patents (Amendment) Ordinance, 2004 for export of pharmaceutical substances, ensures a balance between patent rights and public health is maintained, according to … Continue reading →

Posted in Compulsory Licensing, Doha Declaration | Leave a comment

More Indian drugs detained in EU as FTA talks progress ahead of Feb 10 summit

Posted on January 18, 2012 by

Source: Scripintelligence.com 09 January 2012 Anju Ghangurde Even as the EU and India continue negotiations on a free trade agreement ahead of their next summit in February, another transiting consignment of Indian generics was seized in the EU late last … Continue reading →

Posted in EU-India FTA, IPR Enforcement, seizures, Uncategorized | Leave a comment

Update on first Compulsory License application in India for cancer drug – Sorafenib

Posted on January 17, 2012 by

In the first hearing held on 13 Jan ’12 on Natco’s CL application for Sorafenib (generic version of Bayer’s Nexaver), the Controller General of Patents had asked Bayer, German drug maker to submit cost data, including research and development expenditure on … Continue reading →

Posted in Uncategorized | 1 Comment